Possible Mode ofAction ofPhenelzine
The results of the first two double-blind controlled trials of phenelzine have shown that this monoamine oxidase inhibitor can produce clinical improvement in patients suffering from severe agoraphobia and social phobias. The effect is seen between 4 and 8 weeks and patients relapse if phenelzine is withdrawn prematurely.
It has been postulated that phenelzine acts by reducing the severity and frequency of panic attacks (Kelly et al. 1970) . Once this has happened, patients can enter previously feared situations with less apprehension until, by repeated exposure, avoidance behaviour is diminished and a phobia overcome. Giving phenelzine alone without encouraging the patient to enter phobic situations would probably be less successful.
Phobic patients may differ from normal controls biochemically, because panic attacks can be precipitated much more readily in anxious patients by intravenous sodium lactate (Pitts & McClure 1967 , Kelly et al. 1971 ). We infused 8 severely anxious patients with sodium lactate and this resulted in an anxiety (panic) attack in all of them. They were subsequently treated with phenelzine for a mean duration of 10 weeks. Five of the patients showed marked clinical improvement at the time when a second sodium lactate infusion was administered. The subjective effects produced by the second infusion were considerably reduced in comparison with the prephenelzine infusion. Two patients showed only mild clinical improvement and one patient was unimproved on phenelzine, and in these patients the effects of the second infusion were similar to the first (Kelly et al. 1971) . It thus seems likely that phenelzine only modifies 'lactate-induced' anxiety if it has produced appreciable clinical improvement prior to the infusion, and that it cannot block experimentally induced anxiety in all patients by some nonspecific biochemical mechanism.
The interesting work of Johnstone & Marsh (1973) on depressed patients may enable us to predict by a biochemical examination (rate of acetylation) which phobic patients are likely to respond to phenelzine. If it were known that only phobic patients who were 'slow acetylators' were likely to respond to phenelzine, that would be a considerable advance. At first sight this question may appear unduly provocative; monoamine-oxidase inhibitors (MAOIs) have been in clinical use for sixteen years and have always been classified as antidepressant drugs. This classification has persisted despite abundant evidence that MAOIs are ineffective in severe depressive illness (Stanley & Fleming 1962 , Medical Research Council 1965 . The current view that patients with 'neurotic' depression are best helped by these agents has more to recommend it, but as this category does not hold up as a single diagnostic entity (Pilowsky et al. 1969 , Paykel 1971 , Everitt et al. 1971 it is unjustified to assume that any treatment effective in this condition is antidepressant in mechanism. The difficulties in predicting response to MAOIs in depression are well documented (Pare et al. 1962) ; before considering other mechanisms we should seriously consider whether this is because we have committed the Procrustean error of forcing our patients into a diagnostic category that does not fit them.
The effectiveness of MAOIs in the treatment of phobic anxiety ) is unlikely to be due to an antidepressant action. Phobic anxiety states are clinically distinct from depressive illness (Marks 1969 , Fleiss et al. 1971 , although depression as a symptom may occur in phobic disorders. Our study (Tyrer et al. 1973 ) was deliberately designed to test whether clinical factors were useful predictors of response to phenelzine in chronic agoraphobic and socially phobic patients. We used prospectively matched pairs of patients in which each patient on phenelzine was matched using double-blind procedure with one taking placebo. Provided our criteria for matching were valid, the comparison between the clinical responses of each matched pair gave us the relative contributions of specific drug effects and nonspecific factors. This procedure is the essence of the controlled clinical trial but whereas most such trials are concerned with matched groups our study allowed us to investigate individual responses. The matching criteria used were duration and type of phobia, sex, severity of illness and initial depression rating.
The results showed that duration of phobia was important in predicting response. There was a significant negative correlation between response to phenelzine and duration of illness (r= -0.65: P<0.05): the shorter the illness the better the response. As a similar correlation was found with the placebo group (r= -0.50) this factor is a nonspecific one, but it emphasized that at least one of our criteria was important. Initial depression rating was also negatively correlated with response to phenelzine (r= -0.30) suggesting that a significant degree of depression actually hinders response. There were no differences in response between the sexes and types of phobia.
When the responses of the individual matched pairs were compared, in only one pair did the patient on placebo fare better than the counterpart on phenelzine, and in those with phobia of under ten years' duration all patients on phenelzine were helped appreciably. Although in view of the complexities of assessment the total sample was fairly small, the results show that response to phenelzine can be predicted in phobic anxiety without recourse to biochemical hypotheses. Whatever the mechanism of action, it contradicts the evidence to call it an antidepressant one.
Dr D L F Dunleavy (Department ofPsychiatry, General Hospital, Nottingham, NGJ 6HA)
Mood and Sleep Changes with Monoamine-oxidase Inhibitors
Most drugs used clinically as antidepressants reduce paradoxical or REM sleep, but monoamine-oxidase inhibitors are exceptional in that they totally abolish the signs of REM sleep. Twenty-two depressed patients were monitored in the Sleep Laboratory in Edinburgh throughout their stay in hospital. Each performed a daily self-rating of mood on a visual analogue scale, and there was a deliberately varied placebo period before phenelzine was prescribed in randomly decided, divided daily doses of 60, 75 or 90 mg, the dose remaining constant for each patient.
The results showed that there was a clear-cut dose response relationship, total abolition of the signs of REM sleep occurring in 7-8 days with 75 and 90 mg, and taking 15 days with 60 mg. The daily self-ratings of mood were plotted as a graph for each individual, and given to four psychiatrists, who were told of their general nature, and asked to mark each graph at the point where it appeared that a sustained mood improvement had begun, if at all. All 4 judges unanimously marked the same point on the graph in the case of 6 patients, and 3 out of 4 judges agreed on the response point for a further 3 patients. The 'response points' for these 9 patients were then considered in their temporal relation to the amount of REM sleep as a percentage of the whole night's sleep. On average, the mood response began when the amount of REM sleep had already diminished to about 5% of total sleep, and about two days before abolition of REM sleep. Since the judges scored the take-off points of improvement, the actual first day of improvement would have been a day later, therefore approximating more closely to the mean abolition of REM sleep.
These findings confirm earlier observations that when mood response to phenelzine begins it does so in a temporal association with a profound neurophysiological change that takes up to three weeks to be accomplished after the commencement of the drug. The design of our study was intended to allow comparisons only of time lags, and does not permit firm conclusions to be drawn about the therapeutic use of phenelzine. However, in our view phenelzine is an effective antidepressant for some patients, and thus, if one wishes to influence cerebral function with little delay, 75 mg might be the initial daily dose of choice.
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